Colchicine Effect on Amyotrophic Lateral Sclerosis Patients

ClinicalTrials.gov ID

NCT07813858

Lead Sponsor

Azienda Ospedaliero-Universitaria di ModenaOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

87Estimated

Last Update Posted

Sep 10, 2026Actual

Start Date

Oct 2026Estimated

Primary Completion Date

May 2028Estimated

Completion Date

Dec 2028Estimated

Official Title

A Randomized, Placebo-controlled, Multicenter, Clinical Trial of Colchicine in Amyotrophic Lateral Sclerosis

Brief Summary

The goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder affecting motor neurons.

The study is designed to answer whether patients receiving colchicine show a slower decline in functional status, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), over a 30-week double-blind treatment period compared to patients receiving placebo. Additional questions include whether colchicine has an effect on respiratory function, disability progression, quality of life, and overall survival.

Researchers will compare participants receiving colchicine at a dose of 0.005 mg/kg/day with those receiving placebo, both in addition to standard-of-care therapy with riluzole, to assess potential differences in disease progression.

Participants will be randomly assigned in a 2:1 ratio to colchicine or placebo. They will take the assigned study medication for 30 weeks during a double-blind phase and then continue into a 36-week open-label extension phase, during which all participants will receive colchicine while remaining blinded to their initial treatment assignment. Throughout the study, participants will undergo regular clinical evaluations, including assessments of motor and respiratory function, functional disability, and quality of life, for a total follow-up period of up to 66 weeks. Blood samples will also be collected to investigate biological markers of neurodegeneration and inflammation.

Detailed Description

Co-ALS II is a Phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in specialized ALS referral centers in Italy. The study investigates whether low-dose colchicine (0.005 mg/kg/day) can slow disease progression in patients with Amyotrophic Lateral Sclerosis (ALS), a rapidly progressive neurodegenerative disorder affecting upper and lower motor neurons.

The study is based on emerging evidence supporting a role for impaired proteostasis and neuroinflammation in ALS pathogenesis. In particular, intracellular accumulation of TDP-43 protein aggregates and dysfunction of autophagy-related pathways represent key pathogenic mechanisms. Preclinical data suggest that colchicine may enhance proteostasis mechanisms, including autophagy-related signaling pathways (e.g., TFEB, p62, LC3, and HSPB8), potentially facilitating clearance of toxic protein aggregates.

This hypothesis is further supported by findings from a previous exploratory Phase II study (Co-ALS), which suggested a potential slowing of ALSFRS-R decline with low-dose colchicine, although that study was limited by sample size and external constraints.

In Co-ALS II, 87 patients with definite or probable ALS will be randomized in a 2:1 ratio to receive colchicine or placebo in addition to standard therapy with riluzole. The study includes a screening period of up to 30 days, followed by a 30-week double-blind treatment phase and a 36-week open-label extension phase, resulting in a total follow-up of 66 weeks per participant.

The primary endpoint is the rate of decline in ALSFRS-R score over the 30-week double-blind period. Secondary endpoints include longitudinal changes in ALSFRS-R, Rasch-Built Overall ALS Disability Scale (ROADS), forced vital capacity (FVC), ALS Assessment Questionnaire-40 (ALSAQ-40), functional subdomain scores, and overall survival defined as time to death or tracheostomy.

Biological samples will be collected at baseline, week 30, and week 66 to investigate pharmacodynamic and mechanistic biomarkers. These include neurofilament light chain (NfL), TDP-43 aggregation markers in peripheral blood mononuclear cells, and circulating inflammatory mediators such as MCP-1, GFAP, and TREM2. Optional cerebrospinal fluid and skin biopsy sub-studies will further explore disease biology.

Safety will be closely monitored by an independent Data and Safety Monitoring Board (DSMB), which will periodically review unblinded safety data. Predefined stopping rules are in place for severe hematological or systemic toxicity.

Statistical analyses will compare treatment groups using longitudinal mixed-effects models and non-parametric methods as appropriate. Sample size calculations are based on observed effect sizes from the prior Co-ALS I study, with adjustment for anticipated dropout.

• Amyotrophic Lateral Sclerosis

• Colchicine 0.5 MG Oral Tablet
• Placebo Oral Tablet

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient age strictly between 18 and 80 years at the time of screening.
• Definitively established diagnosis of ALS (sporadic or familial) matching standardized clinical consensus parameters.
• Stable background regimen of European gold-standard Riluzole therapy maintained at a fixed dose of 100 mg/day for a minimum of 1 month prior to baseline randomization.
• BMI>17.5 Kg/m2
• Sufficient respiratory capability, verified by an upright Forced Vital Capacity (FVC) >= 70% of predicted normal values at screening (highest value of three sequential tests).
• Patient must display full cognitive and communicative capacity to provide written, personally signed Independent Ethics Committee-approved Informed Consent prior to initiation of any protocolized procedures.
• Use of highly effective contraception both for males and females

Exclusion Criteria:

• Concurrent participation or treatment within any other interventional or drug-based clinical trial.
• Clinically significant hepatic impairment (defined as baseline serum transaminases AST or ALT exceeding 3x Upper Limit of Normal [ULN], or total bilirubin exceeding 2x ULN).
• Severe renal insufficiency, documented bone marrow suppression, or significant hematological abnormalities.
• Known hypersensitivity or systemic intolerance to colchicine or any of the manufacturing excipients (lactose, sucrose, magnesium stearate, arabic gum).
• Pregnancy, active lactation, or unwillingness of fertile male/female subjects to strictly comply with highly effective double-barrier contraception regimens throughout the study and for 100 days post-final dose.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Azienda Ospedaliero-Universitaria di ModenaOTHER

Collaborators

University of MilanOTHER

Istituto Di Ricerche Farmacologiche Mario NegriOTHER

gianferrari.giulia@aou.mo.it0593961640 ext. +39

ambulatorio.sla@maggioreosp.novara.it0321 3733962 ext. +39

• Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis

  NCT02306590

  CompletedInterventionalNot ApplicableUpdated Feb 26, 2019
• Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis

  NCT00877604

  CompletedInterventionalPhase 2Updated Nov 26, 2014
• Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

  NCT01486849

  CompletedInterventionalPhase 2Updated May 3, 2019
• A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

  NCT01378676

  CompletedInterventionalPhase 2Updated May 7, 2019
• Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

  NCT06126315

  RecruitingInterventionalPhase 2Phase 3Updated Sep 25, 2025
• Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

  NCT00818389

  TerminatedInterventionalPhase 2Phase 3Updated Apr 19, 2011